- Class: Immune checkpoint inhibitor (PD-1 inhibitor)
- Mechanism: Blocks PD-1 receptor on T cells → prevents immune inhibition → promotes anti-tumor response
- Indications:
- Broad: NSCLC, RCC, melanoma, HCC, bladder cancer, esophageal, Hodgkin lymphoma, others
- Often in combination with ipilimumab or chemotherapy
- Dosing:
- Varies by indication:
- Flat dosing (e.g., 240 mg IV q2w or 480 mg q4w)
- Varies by indication:
- Key Toxicities:
- Immune-related toxicities (same class effects as ipilimumab, but usually less severe)
- Pneumonitis, colitis, endocrinopathies, hepatitis, nephritis
- Immune-related toxicities (same class effects as ipilimumab, but usually less severe)
- Monitoring:
- Same labs as ipilimumab (LFTs, thyroid panel, glucose, renal function)
- Signs/symptoms of irAEs
Synonyms
Nivolumab, Opdivo